文献速递妇科

子宫肌瘤子宫切除术中减少出血的围手术期干预:系统综述与Meta分析

Perioperative Interventions to Minimize Blood Loss at the Time of Hysterectomy for Uterine Leiomyomas: A Systematic Review and Meta-analysis.
PubMed 文献 · J Minim Invasive Gynecol · 2019-04-27

该研究系统检索1946年至2018年多个数据库,纳入33项研究(22项定量合成),评估非激素、围手术期手术干预及器械对子宫肌瘤子宫切除术出血的影响。结论:腹部子宫切除术围手术期使用米索前列醇可减少手术出血和术后血红蛋白下降(GRADE证据质量中等),但临床获益可能有限;其他干预至多低质量证据支持。

要点

  • 腹部子宫切除术围手术期使用米索前列醇与术后血红蛋白下降减少(0.59 g/dL)和出血量减少(96.43 mL)相关
  • 腹腔镜子宫切除术中于血管起始处处理子宫血管可减少术中出血(69.07 mL),但术后血红蛋白无显著变化
  • 其他干预(双极电外科器械、EBVS等)与对照相比无显著差异,证据质量至多低

核心结论

  • 腹部子宫切除术围手术期使用米索前列醇可减少手术出血和术后血红蛋白下降(GRADE证据质量中等),但临床获益可能有限。
  • 其余干预虽有前景,但目前至多仅有低质量证据支持其使用。
  • 需要更大规模、严谨设计的随机试验来确定子宫肌瘤子宫切除术的最佳围手术期干预组合。

研究设计与样本

  • 系统综述与Meta分析,由图书馆员主导检索Embase、MEDLINE、Web of Science、Scopus、CINAHL和Cochrane数据库,检索时间1946年至2018年,并手工更新。
  • 共识别2016项独特研究,33项符合纳入标准,其中22项用于定量合成。
  • 排除比较子宫切除术路径、粉碎术、阴道残端缝合、激素药物、阴道子宫切除术血管闭合器械以及少于10例的病例系列。

主要发现

  • 腹部子宫切除术围手术期使用米索前列醇与安慰剂相比,术后血红蛋白下降更少(0.59 g/dL;95%CI 0.39-0.79;p<0.01),出血量更少(-96.43 mL;95%CI -153.52至-39.34;p<0.01)。
  • 腹腔镜子宫切除术中于血管起始处处理子宫血管与经子宫峡部处理相比,术中出血减少(-69.07 mL;95%CI -135.20至-2.95;p=0.04),但术后血红蛋白无显著变化(0.24 g/dL;95%CI -0.31至0.78;p=0.39)。
  • 腹腔镜子宫切除术中在分离卵巢/子宫卵巢血管前结扎子宫动脉与标准结扎相比,手术出血更少(-27.72 mL;95%CI -35.07至-20.38;p<0.01)。
  • 腹部子宫切除术中双极电外科器械与缝合相比,术后血红蛋白下降无显著差异(0.26 g/dL;95%CI -0.19至0.71;p=0.26)。
  • 腹腔镜子宫切除术中电外科双极血管闭合器(EBVS)与常规双极电外科器械相比,血红蛋白下降(0.02 g/dL;95%CI -0.15至0.20;p=0.79)和出血量(-50.88 mL;95%CI -106.44至4.68;p=0.07)均无显著差异;LigaSure阻抗监测EBVS与竞争性EBVS系统(监测阻抗或温度)相比,出血量未减少(2.00 mL;95%CI -8.09至12.09;p=0.70)。

关键数值与推荐

  • 纳入标准:报告子宫切除术、平滑肌瘤及术中出血/术后出血/子宫出血/月经过多/血肿等关键词的研究。
  • 排除标准:比较子宫切除术路径、粉碎术、阴道残端缝合、激素药物、阴道子宫切除术血管闭合器械以及少于10例的病例系列。

临床怎么用

  • 腹部子宫切除术围手术期可考虑使用米索前列醇以减少手术出血和术后血红蛋白下降(GRADE证据质量中等),但临床获益可能有限。
  • 其余干预目前至多仅有低质量证据支持,需更大规模随机试验确定最佳围手术期干预组合。

局限性

  • 其余干预虽有前景,但目前至多仅有低质量证据支持其使用。
  • 需要更大规模、严谨设计的随机试验来确定子宫肌瘤子宫切除术的最佳围手术期干预组合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Hysterectomy for uterine leiomyoma(s) is associated with significant morbidity including blood loss. A systematic review and meta-analysis was conducted to identify nonhormonal interventions, perioperative surgical interventions, and devices to minimize blood loss at the time of hysterectomy for leiomyoma. DATA SOURCES: Librarian-led search of Embase, MEDLINE, Web of Science, Scopus, Cumulative Index to Nursing and Allied Health Literature, and Cochrane databases from 1946 to 2018 with hand-guided updates. METHODS OF STUDY SELECTION: Included studies reported on keywords of hysterectomy, leiomyoma, and operative blood loss/postoperative hemorrhage/uterine bleeding/metrorrhagia/hematoma. The review excluded a comparison of route of hysterectomy, morcellation, vaginal cuff closure, hormonal medications, vessel sealing devices for vaginal hysterectomy, and case series with <10 patients. TABULATION, INTEGRATION, AND RESULTS: Surgical blood loss, postoperative hemoglobin (Hb) drop, hemorrhage, transfusion, and major and minor complications were analyzed and aggregated in meta-analyses for comparable studies in each category. A total of 2016 unique studies were identified, 33 of which met the inclusion criteria, and 22 were used for quantitative synthesis. The perioperative use of misoprostol in abdominal hysterectomy (AH) was associated with a lower postoperative Hb drop (0.59 g/dL; 95% confidence interval [CI], 0.39-0.79; p < .01) and blood loss (-96.43 mL; 95% CI, -153.52 to -39.34; p < .01) compared with placebo. Securing the uterine vessels at their origin in laparoscopic hysterectomy (LH) was associated with decreased intraoperative blood loss (-69.07 mL; 95% CI, -135.20 to -2.95; p = .04) but no significant change in postoperative Hb (0.24 g/dL; 95% CI, -0.31 to 0.78; p = .39) compared with securing them by the uterine isthmus. Uterine artery ligation in LH before dissecting the ovarian/utero-ovarian vessels was associated with lower surgical blood loss compared with standard ligation (-27.72 mL; 95% CI, -35.07 to -20.38; p < .01). The postoperative Hb drop was not significantly different with a bipolar electrosurgical device versus suturing in AH (0.26 g/dL; 95% CI, -0.19 to 0.71; p = .26). There was no significant difference between an electrosurgical bipolar vessel sealer (EBVS) and conventional bipolar electrosurgical devices in the Hb drop (0.02 g/dL; 95% CI, -0.15 to 0.20; p = .79) or blood loss (-50.88 mL; 95% CI, -106.44 to 4.68; p = .07) in LH. Blood loss in LH was not decreased with the LigaSure (Medtronic, Minneapolis, MN) impedance monitoring EBVS compared with competing EBVS systems monitoring impedance or temperature (2.00 mL; 95% CI, -8.09 to 12.09; p = .70). No significant differences in hemorrhage, transfusion, or major complications were noted for all interventions. CONCLUSION: Perioperative misoprostol in AH led to a reduction in surgical blood loss and postoperative Hb drop (moderate level of evidence by Grading of Recommendations, Assessment, Development and Evaluation guidelines) although the clinical benefit is likely limited. Remaining interventions, although promising, had at best low-quality evidence to support their use at this time. Larger and rigorously designed randomized trials are needed to establish the optimal set of perioperative interventions for use in hysterectomy for leiomyomas.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Gingold JA, Chichura A, Harnegie MP, et al. Perioperative Interventions to Minimize Blood Loss at the Time of Hysterectomy for Uterine Leiomyomas: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2019. PMID: 31039407. doi:10.1016/j.jmig.2019.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。